Global Leader in Liver Cell Therapy
Promethera Biosciences develops breakthrough treatment for inborn and acquired liver diseases with no effective therapeutic cure. Their unique cell therapy platforms have different mechanisms of action and focus on 3 main therapeutic pillars: control of inflammatory processes, tissue repair and missing factors/enzymes replacement. With these platforms Promethera focusses on orphan diseases (UCD, ACLF) and larger indications NASH, fibrosis, haemophilia, α1 antitrypsin. Thanks to these technologies and a unique manufacturing process, hundreds of patients can be helped with one liver. Since the acquisition of the key assets of its biggest competitor Cytonet in April 2016, Promethera has access to the largest organ procurement organisation network in the US and a pre-commercial product in the pipeline for the treatment of UCD.